



Shidong Jia - Founder & CEO

- Former Scientist at Genentech and Lab Head at Novartis Institutes for BioMedical Research (NIBR).
- 21 years of experience in cancer research, identified p110 β as novel drug target for PTEN-deficient tumors, a finding that laid the foundation for clinical development of p110 β inhibitors in cancer; 1st authorship publication in Nature.
- 5 years of industry experience spearheading the biomarker strategy and drug & diagnostics co-development efforts in support of oncology pipeline at various stages (i.e., early stage research, late stage research, early development and Phase I and Phase II clinical trials), culminated by the Lifecycle Investment Point (LIP) achievement of driving Phase II into Phase III pivotal clinical trials.
- Member of the National Cancer Institute Special Emphasis Panel Review Committee, the Italian Ministry of Health - Scientific Research and Health Innovation Review Committee.
- Editor-in-Chief of "Journal of Circulating Biomarkers", Springer book "Extracellular Vesicles: Methods and Protocols", and Guest Associate Editor, "Frontiers in Oncology".
- Member of BayHelix, AACR, ASCO, ISEV, and Recipient of the "Young Investigator" award at the Fourth Asian Congress for Microcirculation and the "P.A.R.T. Investigatorship Award" at Dana-Farber Cancer Institute, Harvard Medical School.
- MD, PhD and postdoc from Harbin Medical University, Peking Union Medical College and Harvard University, respectively.

Contact:

sjia@predicine.com

(650) 898-9919